Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebif New Formulation in subjects at high risk of converting to multiple sclerosis
2006-002982-38Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Sep 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of interferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by Merck Serono. Primary endpoint: Time to conversion to multiple sclerosis. Started Sep 2006; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-002982-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002982-38.